VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
351
DELISTED
ACELYRIN
SLRN
| $91.6K | 0.04% |
20,763
+8,862
| +74% | +$39.1K |
|
352
Protagonist Therapeutics
PTGX
$3.77B
| $91.3K | 0.04% |
2,635
-1,540
| -37% | -$53.4K |
|
353
Arvinas
ARVN
$575M
| $91.1K | 0.04% |
3,423
+992
| +41% | +$26.4K |
|
354
Edgewise Therapeutics
EWTX
$1.64B
| $91K | 0.04% |
+5,054
| New | +$91K |
|
355
Arcutis Biotherapeutics
ARQT
$2.06B
| $90.1K | 0.04% |
+9,692
| New | +$90.1K |
|
356
Savara
SVRA
$643M
| $89.9K | 0.04% |
+22,297
| New | +$89.9K |
|
357
Immunovant
IMVT
$2.99B
| $89.8K | 0.04% |
3,403
+1,372
| +68% | +$36.2K |
|
358
Syndax Pharmaceuticals
SNDX
$1.47B
| $89.8K | 0.04% |
4,373
+14
| +0.3% | +$287 |
|
359
Arcellx
ACLX
$4.03B
| $89.6K | 0.04% |
1,623
-65
| -4% | -$3.59K |
|
360
Viridian Therapeutics
VRDN
$1.53B
| $89.6K | 0.04% |
6,884
+2,405
| +54% | +$31.3K |
|
361
Janux Therapeutics
JANX
$1.44B
| $89.5K | 0.04% |
+2,137
| New | +$89.5K |
|
362
NewAmsterdam Pharma
NAMS
$3.04B
| $89.5K | 0.04% |
+4,657
| New | +$89.5K |
|
363
Neumora Therapeutics
NMRA
$272M
| $89.4K | 0.04% |
9,098
+3,180
| +54% | +$31.3K |
|
364
Arrowhead Research
ARWR
$4.02B
| $88.8K | 0.04% |
3,416
+385
| +13% | +$10K |
|
365
Arbutus Biopharma
ABUS
$805M
| $88.5K | 0.04% |
+28,647
| New | +$88.5K |
|
366
HilleVax
HLVX
$105M
| $88.5K | 0.04% |
+6,117
| New | +$88.5K |
|
367
Revolution Medicines
RVMD
$7.57B
| $88.4K | 0.04% |
2,278
-1,033
| -31% | -$40.1K |
|
368
Nuvation Bio
NUVB
$1.33B
| $88.4K | 0.04% |
+30,276
| New | +$88.4K |
|
369
Vera Therapeutics
VERA
$1.54B
| $87.6K | 0.04% |
2,420
-3,466
| -59% | -$125K |
|
370
Prothena Corp
PRTA
$460M
| $87.4K | 0.04% |
4,236
+2,013
| +91% | +$41.5K |
|
371
Summit Therapeutics
SMMT
$19.3B
| $87.3K | 0.04% |
11,190
-21,625
| -66% | -$169K |
|
|
SLN
372
Silence Therapeutics
SLN
$269M
| $87.2K | 0.04% |
+4,591
| New | +$87.2K |
|
373
Nuvalent
NUVL
$5.83B
| $86.9K | 0.04% |
1,146
+50
| +5% | +$3.79K |
|
374
Dianthus Therapeutics
DNTH
$853M
| $86.9K | 0.04% |
+3,358
| New | +$86.9K |
|
|
CRGX
375
DELISTED
CARGO Therapeutics
CRGX
| $86.5K | 0.04% |
+5,269
| New | +$86.5K |
|